Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:34:28.419Z.
Calculation as of: 2026-10-06T17:34:28.419Z.
Quote observation: 2026-10-06T17:29:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 667dd3b64d3a271f66e92979ae52668ccbc7e2b5b2cdee7c8377401ac3ef4785
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$439.38M
PS Ratio
N/A
TTM Avg
46.72
3Y Avg
25.82
5Y Avg
135.95
Market Cap
$420.05M
PS Ratio
3.59
TTM Avg
7.42
3Y Avg
11381.45
5Y Avg
7006.56
Market Cap
$443.46M
PS Ratio
N/A
TTM Avg
70.89
3Y Avg
76.22
5Y Avg
76.22
Market Cap
$443.27M
PS Ratio
280.02
TTM Avg
36.80
3Y Avg
225.33
5Y Avg
298.60
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | $430.29M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $433.60M | 0.57 | 0.42 | 0.50 | 0.63 |
| Assembly Biosciences, Inc. (ASMB)vs › | $434.29M | 5.80 | 6.30 | 5.65 | 8.52 |
| Tilray Brands, Inc. (TLRY)vs › | $425.52M | 0.37 | 0.69 | 0.87 | 1.45 |
| Editas Medicine, Inc. (EDIT)vs › | $426.62M | 9.08 | 6.16 | 8.52 | 20.03 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $439.38M | N/A | 46.72 | 25.82 | 135.95 |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $420.05M | 3.59 | 7.42 | 11381.45 | 7006.56 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $443.46M | N/A | 70.89 | 76.22 | 76.22 |
| Ovid Therapeutics Inc. (OVID)vs › | $443.27M | 280.02 | 36.80 | 225.33 | 298.60 |
| Senseonics Holdings, Inc. (SENS)vs › | $416.81M | 8.59 | 8.95 | 12.76 | 30.61 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
